Home Tools
Log in
Cart
Angiogenesis BTK

BTK

Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.BTK contains five different protein interaction domains. These domains include an amino terminal pleckstrin homology (PH) domain, a proline-rich TEC homology (TH) domain, SRC homology (SH) domains SH2 and SH3, as well as a kinase domain with enzymatic activity.
Cat No. product name
T1835 IbrutinibHOT Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
T6078 SaracatinibHOT Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
T4268 CHMFL-BMX-078 CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
TQ0236 Tirabrutinib Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2 nM).
TQ0230 BTK IN-1 BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
TQ0039 (±)-Zanubrutinib (±)-Zanubrutinib is a specific, potent and orally available Btk inhibitor.
T7584 Zanubrutinib Zanubrutinib is an inhibitor of Bruton tyrosine kinase (BTK).
T5407 BMS986195 BMS986195 is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for BTK...
T5138 BMS986142 BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
T4337 PCI29732 PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
T4391 Syk Inhibitor II (hydrochloride) Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chai...
T9192 BIIB068 BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
T12152 N-piperidine Ibrutinib hydrochloride N-piperidine Ibrutinib hydrochloride is an potent inhibitor of BTK (WT BTK and C481S BTK with IC50s of 51.0 and 30.7 nM, respectively).
T2472 CGI1746 CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
T6217 LFM-A13 LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR...
T3024 Avitinib Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potent...
T3626 Acalabrutinib Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administrat...
T6918 Olmutinib Olmutinib is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. ...
T6921 ONO-4059 analogue ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
T1976 RN486 RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
T2302 CNX774 CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).
TQ0242 Fenebrutinib Fenebrutinib is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
T12311 Tirabrutinib hydrochloride Tirabrutinib hydrochloride is a selective and novelBTK with IC50 2.2 nm inhibitor.
T9125 Tolebrutinib Tolebrutinib is a potent, selective, orally active and brain-penetrant Bruton tyrosine kinase (BTK) inhibitor(IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC...
T10625 IBT6A IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
T9072 BDTX-189 BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reape...
T8636 Ibrutinib deacryloylpiperidine Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
T17098 Tilfrinib Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.
T16853 SB-633825 SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, 1...
T16730 Remibrutinib Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC5...
T12673L PF-06250112 PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase an...
T16441 PCI-33380 PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
T16265 Naluzotan Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiety...
T10629 Btk inhibitor 2 Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).
T12317 Orelabrutinib Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
T11379 GDC-0834 GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and ...
T15365 G-744 G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthriti...
T14956 CHMFL-BTK-01 CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
T14692 BMX-IN-1 BMX-IN-1 is a selective and irreversible bone marrow tyrosine kinase on chromosome X (BMX)inhibitor that targets Cys496 in the BMX ATP binding domain with an IC5...
T14681 BMS-935177 BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk), with an IC50 of 3 nM.
T14357 Spebrutinib besylate Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
T14323 ARQ 531 ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectiv...
T10240 ACP-5862 ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective ...
T12542 PRN1008 PRN1008 is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
T2603 Spebrutinib Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
Ibrutinib HOT
T1835CAS 936563-96-1
Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
Saracatinib HOT
T6078CAS 379231-04-6
Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
CHMFL-BMX-078
T4268CAS 1808288-51-8
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
Tirabrutinib
TQ0236CAS 1351636-18-4
Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2 nM).
BTK IN-1
TQ0230CAS 1270014-40-8
BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
(±)-Zanubrutinib
TQ0039CAS 1633350-06-7
(±)-Zanubrutinib is a specific, potent and orally available Btk inhibitor.
zanubrutinib
T7584CAS 1691249-45-2
Zanubrutinib is an inhibitor of Bruton tyrosine kinase (BTK).
BMS986195
T5407CAS 1912445-55-6
BMS986195 is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for BTK...
BMS986142
T5138CAS 1643368-58-4
BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
PCI29732
T4337CAS 330786-25-9
PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
Syk Inhibitor II (hydrochloride)
T4391CAS 227449-73-2
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chai...
BIIB068
T9192CAS 1798787-27-5
BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
N-piperidine Ibrutinib hydrochloride
T12152CAS 2231747-18-3
N-piperidine Ibrutinib hydrochloride is an potent inhibitor of BTK (WT BTK and C481S BTK with IC50s of 51.0 and 30.7 nM, respectively).
CGI1746
T2472CAS 910232-84-7
CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
LFM-A13
T6217CAS 244240-24-2
LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR...
Avitinib
T3024CAS 1557267-42-1
Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potent...
Acalabrutinib
T3626CAS 1420477-60-6
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administrat...
Olmutinib
T6918CAS 1353550-13-6
Olmutinib is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. ...
ONO-4059 analogue
T6921CAS 1351635-67-0
ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
RN486
T1976CAS 1242156-23-5
RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
CNX774
T2302CAS 1202759-32-7
CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).
Fenebrutinib
TQ0242CAS 1434048-34-6
Fenebrutinib is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
Tirabrutinib hydrochloride
T12311CAS 1439901-97-9
Tirabrutinib hydrochloride is a selective and novelBTK with IC50 2.2 nm inhibitor.
Tolebrutinib
T9125CAS 1971920-73-6
Tolebrutinib is a potent, selective, orally active and brain-penetrant Bruton tyrosine kinase (BTK) inhibitor(IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC...
IBT6A
T10625CAS 1022150-12-4
IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
BDTX-189
T9072CAS 2414572-47-5
BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reape...
Ibrutinib deacryloylpiperidine
T8636CAS 330786-24-8
Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
Tilfrinib
T17098CAS 1600515-49-8
Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.
SB-633825
T16853CAS 956613-01-7
SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, 1...
Remibrutinib
T16730CAS 1787294-07-8
Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC5...
PF-06250112
T12673LCAS 1609465-89-5
PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase an...
PCI-33380
T16441CAS 1022899-36-0
PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
Naluzotan
T16265CAS 740873-06-7
Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiety...
Btk inhibitor 2
T10629CAS 1558036-85-3
Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).
Orelabrutinib
T12317CAS 1655504-04-3
Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
GDC-0834
T11379CAS 1133432-49-1
GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and ...
G-744
T15365CAS 1346669-54-2
G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthriti...
CHMFL-BTK-01
T14956CAS 2095280-64-9
CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
BMX-IN-1
T14692CAS 1431525-23-3
BMX-IN-1 is a selective and irreversible bone marrow tyrosine kinase on chromosome X (BMX)inhibitor that targets Cys496 in the BMX ATP binding domain with an IC5...
BMS-935177
T14681CAS 1231889-53-4
BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk), with an IC50 of 3 nM.
Spebrutinib besylate
T14357CAS 1360053-81-1
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
ARQ 531
T14323CAS 2095393-15-8
ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectiv...
ACP-5862
T10240CAS 2230757-47-6
ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective ...
PRN1008
T12542CAS 1575596-29-0
PRN1008 is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
Spebrutinib
T2603CAS 1202757-89-8
Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.